Log in to your Inderes Free account to see all free content on this page.

Vimian Group

40.95

SEK

-2.73 %

VIMIAN

First North Stockholm

Health Care Providers

Health Care

5 following

-2.73%

-6.93%

-6.08%

+17.84%

+42.88%

+50.08%

-41.95%

-

-47.72%

Vimian Group is a group active in animal health. Through its subsidiaries, the company delivers medicines and technical solutions to veterinarians, laboratories, and pet owners. The products include, for example, drugs with associated clinical research and digital platforms for veterinary clinics. The company operates worldwide and is headquartered in Stockholm.

Market cap

21.45B SEK

Turnover

6.1M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

13.2.

2025

Annual report '24

29.4.

2025

General meeting '24

29.4.

2025

Interim report Q1'25

ShowingAll content types

Vimian Group, Audiocast with teleconference, Q3'24

Webcast10/24/2024, 7:00 AM

Vimian Group, Audiocast with teleconference, Q3'24

Regulatory press release10/24/2024, 5:45 AM

Vimian’s Interim Report for the third quarter of 2024

Press release10/18/2024, 8:00 AM

Invitation to Vimian’s Interim Report for the third quarter of 2024

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release10/11/2024, 8:00 AM

Nomination Committee for Vimian’s 2025 Annual General Meeting

Regulatory press release9/6/2024, 6:04 AM

Vimian Group to enter new MedTech niche through the acquisition of a global veterinary dental company

Vimian Group, Audiocast with teleconference, Q2'24

Webcast8/15/2024, 7:00 AM

Vimian Group, Audiocast with teleconference, Q2'24

Regulatory press release8/15/2024, 5:45 AM

Vimian’s Interim Report for the second quarter of 2024

Press release8/6/2024, 8:00 AM

Invitation to Vimian’s Interim Report for the second quarter of 2024

Press release6/27/2024, 1:30 PM

Fidelio issues call options to Vimian’s Chairman of the Board Magnus Welander

Regulatory press release6/19/2024, 2:30 PM

Conversion of C-shares in Vimian Group AB

Regulatory press release6/11/2024, 6:00 AM

Vimian reaches settlement agreement with one of the main sellers of VOI in the previously announced indemnification process relating to the US patent dispute

Regulatory press release5/22/2024, 10:20 AM

Press release from the Annual General Meeting in Vimian Group AB (publ) on 22 May 2024

Vimian Group, Investor Day, 2024

Webcast5/22/2024, 6:00 AM

Vimian Group, Investor Day, 2024

Vimian Group, Audiocast with teleconference, Q1'24

Webcast5/2/2024, 7:00 AM

Vimian Group, Audiocast with teleconference, Q1'24

Regulatory press release5/2/2024, 5:45 AM

Vimian’s Interim Report for the first quarter of 2024

Press release4/22/2024, 8:00 AM

Invitation to Vimian’s Interim Report for the first quarter of 2024

Regulatory press release4/19/2024, 6:30 AM

Notice of Annual General Meeting in Vimian Group AB (publ)

Regulatory press release4/10/2024, 6:00 AM

Vimian publishes Annual Report and Sustainability Report for 2023

Regulatory press release4/5/2024, 6:00 AM

Vimian announces final outcome in the oversubscribed rights issue

Regulatory press release3/18/2024, 11:45 AM

Vimian publishes prospectus regarding the rights issue

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.